PMC:7195088 / 34333-34650 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1022","span":{"begin":211,"end":219},"obj":"Species"},{"id":"1023","span":{"begin":275,"end":286},"obj":"Chemical"},{"id":"1024","span":{"begin":288,"end":299},"obj":"Chemical"},{"id":"1025","span":{"begin":304,"end":315},"obj":"Chemical"},{"id":"1026","span":{"begin":71,"end":79},"obj":"Disease"},{"id":"1027","span":{"begin":225,"end":233},"obj":"Disease"}],"attributes":[{"id":"A1022","pred":"tao:has_database_id","subj":"1022","obj":"Tax:9606"},{"id":"A1023","pred":"tao:has_database_id","subj":"1023","obj":"MESH:C540383"},{"id":"A1024","pred":"tao:has_database_id","subj":"1024","obj":"MESH:C000596027"},{"id":"A1025","pred":"tao:has_database_id","subj":"1025","obj":"MESH:C479163"},{"id":"A1026","pred":"tao:has_database_id","subj":"1026","obj":"MESH:C000657245"},{"id":"A1027","pred":"tao:has_database_id","subj":"1027","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Off-label drugs mostly provided in Italy during the first phase of the COVID-19 pandemic according to the authors' direct experience. Of note, there are also registered RCT for other drugs to be investigated in patients with COVID-19 (e.g. the Janus kinase family inhibitors ruxolitinib, baricitinib and tofacitinib)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T176","span":{"begin":71,"end":79},"obj":"Disease"},{"id":"T177","span":{"begin":225,"end":233},"obj":"Disease"}],"attributes":[{"id":"A176","pred":"mondo_id","subj":"T176","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A177","pred":"mondo_id","subj":"T177","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Off-label drugs mostly provided in Italy during the first phase of the COVID-19 pandemic according to the authors' direct experience. Of note, there are also registered RCT for other drugs to be investigated in patients with COVID-19 (e.g. the Janus kinase family inhibitors ruxolitinib, baricitinib and tofacitinib)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T191","span":{"begin":4,"end":9},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"}],"text":"Off-label drugs mostly provided in Italy during the first phase of the COVID-19 pandemic according to the authors' direct experience. Of note, there are also registered RCT for other drugs to be investigated in patients with COVID-19 (e.g. the Janus kinase family inhibitors ruxolitinib, baricitinib and tofacitinib)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T468","span":{"begin":4,"end":9},"obj":"Chemical"},{"id":"T469","span":{"begin":10,"end":15},"obj":"Chemical"},{"id":"T470","span":{"begin":183,"end":188},"obj":"Chemical"},{"id":"T471","span":{"begin":264,"end":274},"obj":"Chemical"},{"id":"T472","span":{"begin":275,"end":286},"obj":"Chemical"},{"id":"T473","span":{"begin":304,"end":315},"obj":"Chemical"}],"attributes":[{"id":"A468","pred":"chebi_id","subj":"T468","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A469","pred":"chebi_id","subj":"T469","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A470","pred":"chebi_id","subj":"T470","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A471","pred":"chebi_id","subj":"T471","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A472","pred":"chebi_id","subj":"T472","obj":"http://purl.obolibrary.org/obo/CHEBI_66919"},{"id":"A473","pred":"chebi_id","subj":"T473","obj":"http://purl.obolibrary.org/obo/CHEBI_71200"}],"text":"Off-label drugs mostly provided in Italy during the first phase of the COVID-19 pandemic according to the authors' direct experience. Of note, there are also registered RCT for other drugs to be investigated in patients with COVID-19 (e.g. the Janus kinase family inhibitors ruxolitinib, baricitinib and tofacitinib)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T277","span":{"begin":0,"end":133},"obj":"Sentence"},{"id":"T278","span":{"begin":134,"end":317},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Off-label drugs mostly provided in Italy during the first phase of the COVID-19 pandemic according to the authors' direct experience. Of note, there are also registered RCT for other drugs to be investigated in patients with COVID-19 (e.g. the Janus kinase family inhibitors ruxolitinib, baricitinib and tofacitinib)."}